Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanomaAvinash Gupta, Valentine M. Macaulay|British Journal of Cancer|2019Cited by 30
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Aleigha Lawless et al.|EClinicalMedicine|2023Cited by 26
803P Patient-reported outcomes in patients with resected, stage III BRAF V600+ melanoma treated with adjuvant dabrafenib + trametinib: COMBI-APlus studyJean‐Jacques Grob, Victoria Atkinson, Caroline Dutriaux et al.|Annals of Oncology|2022Cited by 2